Literature DB >> 16793529

Screening in a spirit haunted world.

Brian K Shoichet1.   

Abstract

High-throughput screening (HTS) campaigns can be dominated by hits that ultimately turn out to be non-drug-like. These "nuisance" compounds often behave strangely, with steep dose-response curves, absence of clear structure-activity relationships, and high sensitivity to assay conditions. Several mechanisms contribute to these artifacts, including chemically reactive molecules, those that absorb light in assays and those that affect redox conditions. One of the most common mechanisms behind artifactual inhibition is discussed in this review: at micromolar concentrations organic molecules can aggregate to form particles in aqueous buffers, and these aggregates can sequester and thereby inhibit protein targets. Aggregation-based inhibition is baffling from a chemical perspective, but viewed biophysically such behavior is expected. The range of molecules that behave this way, their rapid detection in a screening environment and their possible biological implications will be considered here.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793529      PMCID: PMC1524586          DOI: 10.1016/j.drudis.2006.05.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries.

Authors:  Olivier Roche; Petra Schneider; Jochen Zuegge; Wolfgang Guba; Manfred Kansy; Alexander Alanine; Konrad Bleicher; Franck Danel; Eva-Maria Gutknecht; Mark Rogers-Evans; Werner Neidhart; Henri Stalder; Michael Dillon; Eric Sjögren; Nader Fotouhi; Paul Gillespie; Robert Goodnow; William Harris; Phil Jones; Mikio Taniguchi; Shinji Tsujii; Wolfgang von der Saal; Gerd Zimmermann; Gisbert Schneider
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

2.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

3.  Kinase inhibitors: not just for kinases anymore.

Authors:  Susan L McGovern; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

Review 4.  Designing screens: how to make your hits a hit.

Authors:  W Patrick Walters; Mark Namchuk
Journal:  Nat Rev Drug Discov       Date:  2003-04       Impact factor: 84.694

Review 5.  Nonleadlikeness and leadlikeness in biochemical screening.

Authors:  Gilbert M Rishton
Journal:  Drug Discov Today       Date:  2003-01-15       Impact factor: 7.851

6.  Effect of detergent on "promiscuous" inhibitors.

Authors:  Ali J Ryan; Norman M Gray; Peter N Lowe; Chun-wa Chung
Journal:  J Med Chem       Date:  2003-07-31       Impact factor: 7.446

7.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

8.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

9.  Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.

Authors:  Yulia Volovik Frenkel; Arthur D Clark; Kalyan Das; Yuh-Hwa Wang; Paul J Lewi; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

10.  Detailed kinetic studies of an aggregating inhibitor; inhibition of phosphomannomutase/phosphoglucomutase by disperse blue 56.

Authors:  Hao-Yang Liu; Ziaohui Wang; Catherine Regni; Xiaoqin Zou; Peter A Tipton
Journal:  Biochemistry       Date:  2004-07-13       Impact factor: 3.162

View more
  89 in total

1.  Microfluidics: Analog-to-digital drug screening.

Authors:  Robert C R Wootton; Andrew J Demello
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

2.  Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.

Authors:  Abhinav Nath; Michael A Zientek; Benjamin J Burke; Ying Jiang; William M Atkins
Journal:  Drug Metab Dispos       Date:  2010-09-14       Impact factor: 3.922

Review 3.  Design and implementation of high throughput screening assays.

Authors:  Ricardo Macarrón; Robert P Hertzberg
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

4.  Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.

Authors:  Katherine A Rawls; Christoph Grundner; Jonathan A Ellman
Journal:  Org Biomol Chem       Date:  2010-07-19       Impact factor: 3.876

5.  How to Triage PAINS-Full Research.

Authors:  Jayme L Dahlin; Michael A Walters
Journal:  Assay Drug Dev Technol       Date:  2015-10-23       Impact factor: 1.738

Review 6.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

7.  Divergent modes of enzyme inhibition in a homologous structure-activity series.

Authors:  Rafaela S Ferreira; Clifford Bryant; Kenny K H Ang; James H McKerrow; Brian K Shoichet; Adam R Renslo
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

8.  Development of a novel high-throughput screen and identification of small-molecule inhibitors of the Gα-RGS17 protein-protein interaction using AlphaScreen.

Authors:  Duncan I Mackie; David L Roman
Journal:  J Biomol Screen       Date:  2011-06-16

9.  Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.

Authors:  Filip Miljković; Martin Vogt; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-03-26       Impact factor: 3.686

10.  The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia).

Authors:  Lakshmi Ganesan; Peter Buchwald
Journal:  J Mol Recognit       Date:  2013-04       Impact factor: 2.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.